M&A Deal Summary |
|
|---|---|
| Date | 2015-04-09 |
| Target | PersonalizeDx |
| Sector | Life Science |
| Buyer(s) | Rosetta Genomics |
| Sellers(s) | Prelude |
| Deal Type | Divestiture |
| Deal Value | 2M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2000 |
| Sector | Life Science |
| Employees | 52 |
| Revenue | 1M USD (2014) |
Rosetta Genomics Ltd. is a developer and provider of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-03-05 |
PersonalizeDx
Lake Forest, California, United States PersonalizeDx Labs provides as a service molecular tests in pharmacogenomics, genetic disorders, oncology and infectious disease which will serve as a valuable aid for clinicians in diagnosing patients early and enable appropriate therapeutic intervention to enhance patient care. |
Sell | $1M |
Prelude Corp. is a developer of prognostic test for ductal carcinoma in situ (DCIS). Prelude’s proprietary risk algorithms combine results from a panel of biomarkers that reveal a patient’s DCIS biology.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
